Extended Data Fig. 2: Mutation densities at chromosomal gains in the discovery cohort.
From: Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome
a, Mutation densities of non-amplified clonal mutations per genomic segment, stratified by copy number for tumor NBE15. Significance was tested with a two-sided Wilcoxon rank sum test/Mann–Whitney U-test (disomic: n = 15; trisomic: n = 6; tetrasomic: n = 3). Boxes show median, 25% and 75% percentiles, whiskers extend to the smallest and largest value within 1.5x interquartile range. b, Estimated mutation densities at ECA and MRCA of primary tumors (ECA: n = 26; MRCA: n = 60), primary metastases (ECA: n = 2; MRCA: n = 7) and relapsed tumors/metastases (ECA: n = 30; MRCA: n = 33). Significance was tested with a two-sided Wilcoxon rank sum test/Mann–Whitney U-test and defining ** as P < 0.01 (exact P values are given in Source Data). c, Model scheme for neuroblastoma relapse corresponding to data in (b). d and e, Exposures of mutational signatures among clonal (d) and subclonal SSNVs (e). Signatures SBS1, SBS5 and SBS40 were combined into a single clock-like mutational signature. Bar heights correspond to the average among early-MRCA (top; n = 20 primary tumors and metastases) and late-MRCA tumors (bottom; n = 47 primary tumors and metastases); error bars show standard error of the mean.
